Single shot for psoriasis? study probes why some see lasting relief
NCT ID NCT04630652
Summary
This study aims to understand why a single dose of the psoriasis drug risankizumab (Skyrizi) can lead to long-term skin clearance for some people, even after stopping treatment. Researchers will analyze skin samples from 20 adults with moderate-to-severe psoriasis to see how the drug changes their immune cells. The goal is to learn how to predict which patients might achieve lasting remission from just a short course of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Rockefeller Univesity
New York, New York, 10065, United States
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
-
VA Northern California Health Care System
Sacramento, California, 95655, United States
Conditions
Explore the condition pages connected to this study.